Connecting Molecules to Medicine™
See What Makes Nexus Pharmaceuticals Different
Through our commitment to innovative R&D, Nexus Pharmaceuticals identifies off-patent and difficult to formulate molecules that can be developed, improved upon, and commercialized to advance industry standards and deliver on critical medical needs.
Opening in Summer 2021
State-of-the-Art Sterile Injectable Manufacturing Facility
Located in Pleasant Prairie, Wisconsin, we broke ground in 2019 to build Project Tomorrow, a state-of-the-art sterile injectable manufacturing facility to support the production and supply of injectable drugs in various therapeutic areas including anesthesiology, oncology, cardiology, and neurology. We plan to invest $250 million over the next ten years and create over 400 jobs in total.
Nexus is proud to partner with the University of Wisconsin-Parkside and Parkside Athletics in support of their #RangerVision2020 campaign to secure a brighter future for student-athletes, the Parkside Athletics program, and the Wisconsin community.
Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.
Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
Find out what we’re about
Discover more about Nexus Pharmaceuticals and get in touch today!